Nasdaq

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates ...
ascopubs.org

TRICK-MCC: A proof-of-concept, investigator-initiated study of combination therapy with anti–PD-1, anti–LAG-3, and anti–TIM-3 in participants with advanced or metastatic ...

Intralesional administration of L19IL2/L19TNF in high-risk locally advanced basal cell carcinoma or cutaneous squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Business Insider

ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer

Exploring the combination with atezolizumab and radiation therapy Study led by Yale University MADRID, Spain and CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ...
Seeking Alpha

Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for ...

SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 / Jaguar Health, Inc. (JAGX) (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of two independent ...
ascopubs.org

An open-label single-center investigator-initiated exploratory clinical study in patients with refractory or recurrent solid tumors using SBRT as “in situ vaccination”: R ...

A phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA). This is an ...
Sacramento Bee

Two Investigator-Initiated Responder Analysis Trials of Jaguar Health’s Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted ...

SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 /Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of two independent ...